INDAPAMIDE
4 general benefit · 2 not a benefit
Other products in the same Health Canada class (C03BA) — coverage varies; not interchangeable
- Chlorthalidone (Hygroton): general benefit, Not a benefit
- Metolazone (Zaroxolyn): general benefit
Apo-Indapamide · DIN 02245246 · 1.25mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Indapamide · DIN 02245246
Manufacturer: Apotex Inc.; listing date 2003-04-16
Health Canada: Marketed since 2002-11-08 · brand APO-INDAPAMIDE 1.25 MG TABLETS · ATC C03BA11 INDAPAMIDE · form Tablet · route Oral · ingredients INDAPAMIDE 1.25 MG · company Apotex inc · schedule Prescription
Apo-Indapamide: Formulary list price $0.1490/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1490 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69270 · Verify on the e-Formulary ↗ (DIN 02245246)
Source record
DIN 02245246: Apo-Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800040; group id 564; item number 1507; lccId None; manufacturer id APX
Source form: Tab; strength: 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1490; ministry $0.1490
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245246
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69270
Interchangeable products
Lozide · DIN 02179709 · not recorded
Mylan-Indapamide · DIN 02240067 · $0.1490
Shortage status: resolved shortage (ended 2023-11-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245246
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mylan-Indapamide · DIN 02240067 · 1.25mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Indapamide · DIN 02240067
Manufacturer: Mylan Pharmaceuticals ULC; listing date 1999-09-15
Health Canada: Marketed since 2009-11-13 · brand MYLAN-INDAPAMIDE · ATC C03BA11 INDAPAMIDE · form Tablet · route Oral · ingredients INDAPAMIDE 1.25 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Indapamide: Formulary list price $0.1490/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1490 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63577 · Verify on the e-Formulary ↗ (DIN 02240067)
Source record
DIN 02240067: Mylan-Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800040; group id 564; item number 1507; lccId None; manufacturer id MYL
Source form: Tab; strength: 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.1490; ministry $0.1490
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240067
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63577
Interchangeable products
Apo-Indapamide · DIN 02245246 · $0.1490
Lozide · DIN 02179709 · not recorded
Shortage status: shortage reported ended 2026-07-13 (report last updated 2026-07-13); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02240067
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Indapamide · DIN 02223678 · 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Indapamide · DIN 02223678
Manufacturer: Apotex Inc.; listing date 1996-12-19
Daily cost (source): $0.2364
Health Canada: Marketed since 2002-01-22 · brand APO-INDAPAMIDE 2.5MG TABLETS · ATC C03BA11 INDAPAMIDE · form Tablet · route Oral · ingredients INDAPAMIDE 2.5 MG · company Apotex inc · schedule Prescription
Apo-Indapamide: Formulary list price $0.2364/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2364 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43381 · Verify on the e-Formulary ↗ (DIN 02223678)
Source record
DIN 02223678: Apo-Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800036; group id 564; item number 1508; lccId None; manufacturer id APX
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2364; ministry $0.2364
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02223678
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43381
Interchangeable products
Lozide · DIN 00564966 · not recorded
Mylan-Indapamide · DIN 02153483 · $0.2364
Shortage status: resolved shortage (ended 2023-08-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02223678
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Mylan-Indapamide · DIN 02153483 · 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mylan-Indapamide · DIN 02153483
Manufacturer: Mylan Pharmaceuticals ULC; listing date 1996-10-01
Daily cost (source): $0.2364
Health Canada: Marketed since 2009-11-16 · brand MYLAN-INDAPAMIDE · ATC C03BA11 INDAPAMIDE · form Tablet · route Oral · ingredients INDAPAMIDE 2.5 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Mylan-Indapamide: Formulary list price $0.2364/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2364 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18065 · Verify on the e-Formulary ↗ (DIN 02153483)
Source record
DIN 02153483: Mylan-Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 402800036; group id 564; item number 1508; lccId None; manufacturer id MYL
Source form: Tab; strength: 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2364; ministry $0.2364
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02153483
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18065
Interchangeable products
Apo-Indapamide · DIN 02223678 · $0.2364
Lozide · DIN 00564966 · not recorded
Shortage status: resolved shortage (ended 2026-03-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02153483
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Lozide · DIN 02179709 · 1.25mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-09-21 — choose a marketed DIN from the same-category list.Discontinued 2021-09-21 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2021-09-21 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-09-21 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lozide · DIN 02179709
Manufacturer: Servier Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2021-09-21 · brand LOZIDE · ATC C03BA11 INDAPAMIDE · form Tablet · route Oral · ingredients INDAPAMIDE 1.25 MG · company Servier canada inc · schedule Prescription
Lozide: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19089 · Verify on the e-Formulary ↗ (DIN 02179709)
Source record
DIN 02179709: Lozide
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 402800040; group id 564; item number 1507; lccId None; manufacturer id SEV
Source form: Tab; strength: 1.25mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02179709
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19089
Interchangeable products
Apo-Indapamide · DIN 02245246 · $0.1490
Mylan-Indapamide · DIN 02240067 · $0.1490
Shortage status: discontinued (2021-09-21, reported by SERVIER CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02179709
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-09-21 — choose a marketed DIN from the same-category list.
Lozide · DIN 00564966 · 2.5mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-08-31 — choose a marketed DIN from the same-category list.Discontinued 2020-08-31 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-08-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-08-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Lozide · DIN 00564966
Manufacturer: Servier Canada Inc.; listing date 1996-10-01
Daily cost (source): $0.2364
Health Canada: Cancelled post market since 2020-08-31 · brand LOZIDE · ATC C03BA11 INDAPAMIDE · form Tablet · route Oral · ingredients INDAPAMIDE 2.5 MG · company Servier canada inc · schedule Prescription
Lozide: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4857 · Verify on the e-Formulary ↗ (DIN 00564966)
Source record
DIN 00564966: Lozide
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 402800036; group id 564; item number 1508; lccId None; manufacturer id SEV
Source form: Tab; strength: 2.5mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00564966
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=4857
Interchangeable products
Apo-Indapamide · DIN 02223678 · $0.2364
Mylan-Indapamide · DIN 02153483 · $0.2364
Shortage status: resolved shortage (ended 2020-08-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00564966
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-08-31 — choose a marketed DIN from the same-category list.
PERINDOPRIL ERBUMINE & INDAPAMIDE
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.
Other products in the same Health Canada class (C03BA) — coverage varies; not interchangeable
- Chlorthalidone (Hygroton): general benefit, Not a benefit
- Metolazone (Zaroxolyn): general benefit
Coversyl Plus LD · DIN 02246568 · 2mg & 0.625mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Coversyl Plus LD · DIN 02246568
Manufacturer: Servier Canada Inc.; listing date 2007-04-02
Health Canada: Marketed since 2007-10-02 · brand COVERSYL PLUS LD · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG, INDAPAMIDE 0.625 MG · company Servier canada inc · schedule Prescription
Ministry pays: $0.2113 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70751 · Verify on the e-Formulary ↗ (DIN 02246568)
Source record
DIN 02246568: Coversyl Plus LD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800265; group id 344; item number 0781; lccId None; manufacturer id SEV
Source form: Tab; strength: 2mg & 0.625mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.0357; ministry $0.2113
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246568
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70751
Interchangeable products
Jamp Perindopril / Indapamide · DIN 02554119 · $0.2113
PMS-Perindopril-Indapamide · DIN 02537990 · $0.2113
Sandoz Perindopril Erbumine/IndapamideLD · DIN 02470411 · $0.2113
Shortage status: resolved shortage (ended 2023-05-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246568
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Perindopril / Indapamide · DIN 02554119 · 2mg & 0.625mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Perindopril / Indapamide · DIN 02554119
Manufacturer: Jamp Pharma Corporation; listing date 2026-01-30
Health Canada: Marketed since 2025-12-16 · brand JAMP PERINDOPRIL/INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG, INDAPAMIDE 0.625 MG · company Jamp pharma corporation · schedule Prescription
Jamp Perindopril / Indapamide: Formulary list price $0.2113/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2113 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104299 · Verify on the e-Formulary ↗ (DIN 02554119)
Source record
DIN 02554119: Jamp Perindopril / Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800265; group id 344; item number 0781; lccId None; manufacturer id JPC
Source form: Tab; strength: 2mg & 0.625mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2113; ministry $0.2113
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554119
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104299
Interchangeable products
Coversyl Plus LD · DIN 02246568 · $0.2113
PMS-Perindopril-Indapamide · DIN 02537990 · $0.2113
Sandoz Perindopril Erbumine/IndapamideLD · DIN 02470411 · $0.2113
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02554119
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Perindopril-Indapamide · DIN 02537990 · 2mg & 0.625mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Perindopril-Indapamide · DIN 02537990
Manufacturer: Pharmascience Inc.; listing date 2023-10-31
Health Canada: Marketed since 2023-08-29 · brand PMS-PERINDOPRIL-INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients INDAPAMIDE 0.625 MG, PERINDOPRIL ERBUMINE 2 MG · company Pharmascience inc · schedule Prescription
PMS-Perindopril-Indapamide: Formulary list price $0.2113/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2113 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102673 · Verify on the e-Formulary ↗ (DIN 02537990)
Source record
DIN 02537990: PMS-Perindopril-Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800265; group id 344; item number 0781; lccId None; manufacturer id PMS
Source form: Tab; strength: 2mg & 0.625mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2113; ministry $0.2113
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02537990
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102673
Interchangeable products
Coversyl Plus LD · DIN 02246568 · $0.2113
Jamp Perindopril / Indapamide · DIN 02554119 · $0.2113
Sandoz Perindopril Erbumine/IndapamideLD · DIN 02470411 · $0.2113
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02537990
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Perindopril Erbumine/IndapamideLD · DIN 02470411 · 2mg & 0.625mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Perindopril Erbumine/IndapamideLD · DIN 02470411
Manufacturer: Sandoz Canada Inc.; listing date 2018-04-30
Health Canada: Marketed since 2018-03-05 · brand SANDOZ PERINDOPRIL ERBUMINE/ INDAPAMIDE LD · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 2 MG, INDAPAMIDE 0.625 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Perindopril Erbumine/IndapamideLD: Formulary list price $0.2113/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2113 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95939 · Verify on the e-Formulary ↗ (DIN 02470411)
Source record
DIN 02470411: Sandoz Perindopril Erbumine/IndapamideLD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800265; group id 344; item number 0781; lccId None; manufacturer id SDZ
Source form: Tab; strength: 2mg & 0.625mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2113; ministry $0.2113
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02470411
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95939
Interchangeable products
Coversyl Plus LD · DIN 02246568 · $0.2113
Jamp Perindopril / Indapamide · DIN 02554119 · $0.2113
PMS-Perindopril-Indapamide · DIN 02537990 · $0.2113
Shortage status: resolved shortage (ended 2023-09-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02470411
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Perindopril-Indapamide · DIN 02297574 · 4mg & 1.25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Perindopril-Indapamide · DIN 02297574
Manufacturer: Apotex Inc.; listing date 2021-03-29
Health Canada: Marketed since 2021-02-02 · brand APO-PERINDOPRIL-INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG, INDAPAMIDE 1.25 MG · company Apotex inc · schedule Prescription
Apo-Perindopril-Indapamide: Formulary list price $0.2556/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2556 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78291 · Verify on the e-Formulary ↗ (DIN 02297574)
Source record
DIN 02297574: Apo-Perindopril-Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800264; group id 344; item number 0782; lccId None; manufacturer id APX
Source form: Tab; strength: 4mg & 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2556; ministry $0.2556
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02297574
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78291
Interchangeable products
Coversyl Plus · DIN 02246569 · $0.2556
Jamp Perindopril / Indapamide · DIN 02554127 · $0.2556
PMS-Perindopril-Indapamide · DIN 02538008 · $0.2556
Perindopril Erbumine/Indapamide · DIN 02479834 · $0.2556
Perindopril/Indapamide · DIN 02519720 · $0.2556
Sandoz Perindopril Erbumine/Indapamide · DIN 02470438 · $0.2556
Teva-Perindopril/Indapamide · DIN 02464020 · $0.2556
Shortage status: active shortage (reported 2026-02-10, last updated 2026-02-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02297574
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Coversyl Plus · DIN 02246569 · 4mg & 1.25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Coversyl Plus (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Coversyl Plus · DIN 02246569
Manufacturer: Servier Canada Inc.; listing date 2007-04-02
Health Canada: Marketed since 2003-10-10 · brand COVERSYL PLUS · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG, INDAPAMIDE 1.25 MG · company Servier canada inc · schedule Prescription
Ministry pays: $0.2556 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70752 · Verify on the e-Formulary ↗ (DIN 02246569)
Source record
DIN 02246569: Coversyl Plus
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800264; group id 344; item number 0782; lccId None; manufacturer id SEV
Source form: Tab; strength: 4mg & 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.2317; ministry $0.2556
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246569
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=70752
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02297574 · $0.2556
Jamp Perindopril / Indapamide · DIN 02554127 · $0.2556
PMS-Perindopril-Indapamide · DIN 02538008 · $0.2556
Perindopril Erbumine/Indapamide · DIN 02479834 · $0.2556
Perindopril/Indapamide · DIN 02519720 · $0.2556
Sandoz Perindopril Erbumine/Indapamide · DIN 02470438 · $0.2556
Teva-Perindopril/Indapamide · DIN 02464020 · $0.2556
Shortage status: resolved shortage (ended 2020-11-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02246569
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Perindopril / Indapamide · DIN 02554127 · 4mg & 1.25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Perindopril / Indapamide · DIN 02554127
Manufacturer: Jamp Pharma Corporation; listing date 2026-01-30
Health Canada: Marketed since 2025-12-16 · brand JAMP PERINDOPRIL/INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 4 MG, INDAPAMIDE 1.25 MG · company Jamp pharma corporation · schedule Prescription
Jamp Perindopril / Indapamide: Formulary list price $0.2556/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2556 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104300 · Verify on the e-Formulary ↗ (DIN 02554127)
Source record
DIN 02554127: Jamp Perindopril / Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800264; group id 344; item number 0782; lccId None; manufacturer id JPC
Source form: Tab; strength: 4mg & 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2556; ministry $0.2556
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554127
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104300
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02297574 · $0.2556
Coversyl Plus · DIN 02246569 · $0.2556
PMS-Perindopril-Indapamide · DIN 02538008 · $0.2556
Perindopril Erbumine/Indapamide · DIN 02479834 · $0.2556
Perindopril/Indapamide · DIN 02519720 · $0.2556
Sandoz Perindopril Erbumine/Indapamide · DIN 02470438 · $0.2556
Teva-Perindopril/Indapamide · DIN 02464020 · $0.2556
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02554127
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Perindopril-Indapamide · DIN 02538008 · 4mg & 1.25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Perindopril-Indapamide · DIN 02538008
Manufacturer: Pharmascience Inc.; listing date 2023-10-31
Health Canada: Marketed since 2023-08-29 · brand PMS-PERINDOPRIL-INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients INDAPAMIDE 1.25 MG, PERINDOPRIL ERBUMINE 4 MG · company Pharmascience inc · schedule Prescription
PMS-Perindopril-Indapamide: Formulary list price $0.2556/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2556 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102674 · Verify on the e-Formulary ↗ (DIN 02538008)
Source record
DIN 02538008: PMS-Perindopril-Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800264; group id 344; item number 0782; lccId None; manufacturer id PMS
Source form: Tab; strength: 4mg & 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2556; ministry $0.2556
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02538008
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102674
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02297574 · $0.2556
Coversyl Plus · DIN 02246569 · $0.2556
Jamp Perindopril / Indapamide · DIN 02554127 · $0.2556
Perindopril Erbumine/Indapamide · DIN 02479834 · $0.2556
Perindopril/Indapamide · DIN 02519720 · $0.2556
Sandoz Perindopril Erbumine/Indapamide · DIN 02470438 · $0.2556
Teva-Perindopril/Indapamide · DIN 02464020 · $0.2556
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02538008
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Perindopril Erbumine/Indapamide · DIN 02479834 · 4mg & 1.25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Perindopril Erbumine/Indapamide · DIN 02479834
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2022-03-31
Health Canada: Marketed since 2022-01-20 · brand PERINDOPRIL ERBUMINE/ INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients INDAPAMIDE 1.25 MG, PERINDOPRIL ERBUMINE 4 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Perindopril Erbumine/Indapamide: Formulary list price $0.2556/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2556 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97039 · Verify on the e-Formulary ↗ (DIN 02479834)
Source record
DIN 02479834: Perindopril Erbumine/Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800264; group id 344; item number 0782; lccId None; manufacturer id SIV
Source form: Tab; strength: 4mg & 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2556; ministry $0.2556
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479834
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97039
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02297574 · $0.2556
Coversyl Plus · DIN 02246569 · $0.2556
Jamp Perindopril / Indapamide · DIN 02554127 · $0.2556
PMS-Perindopril-Indapamide · DIN 02538008 · $0.2556
Perindopril/Indapamide · DIN 02519720 · $0.2556
Sandoz Perindopril Erbumine/Indapamide · DIN 02470438 · $0.2556
Teva-Perindopril/Indapamide · DIN 02464020 · $0.2556
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02479834
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Perindopril/Indapamide · DIN 02519720 · 4mg & 1.25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Perindopril/Indapamide · DIN 02519720
Manufacturer: Sanis Health Inc.; listing date 2022-02-28
Health Canada: Marketed since 2021-12-15 · brand PERINDOPRIL/INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients INDAPAMIDE 1.25 MG, PERINDOPRIL ERBUMINE 4 MG · company Sanis health inc · schedule Prescription
Perindopril/Indapamide: Formulary list price $0.2556/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2556 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100896 · Verify on the e-Formulary ↗ (DIN 02519720)
Source record
DIN 02519720: Perindopril/Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800264; group id 344; item number 0782; lccId None; manufacturer id SAI
Source form: Tab; strength: 4mg & 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2556; ministry $0.2556
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519720
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100896
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02297574 · $0.2556
Coversyl Plus · DIN 02246569 · $0.2556
Jamp Perindopril / Indapamide · DIN 02554127 · $0.2556
PMS-Perindopril-Indapamide · DIN 02538008 · $0.2556
Perindopril Erbumine/Indapamide · DIN 02479834 · $0.2556
Sandoz Perindopril Erbumine/Indapamide · DIN 02470438 · $0.2556
Teva-Perindopril/Indapamide · DIN 02464020 · $0.2556
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519720
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Sandoz Perindopril Erbumine/Indapamide · DIN 02470438 · 4mg & 1.25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Sandoz Perindopril Erbumine/Indapamide · DIN 02470438
Manufacturer: Sandoz Canada Inc.; listing date 2018-04-30
Health Canada: Marketed since 2018-03-05 · brand SANDOZ PERINDOPRIL ERBUMINE/ INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients INDAPAMIDE 1.25 MG, PERINDOPRIL ERBUMINE 4 MG · company Sandoz canada incorporated · schedule Prescription
Sandoz Perindopril Erbumine/Indapamide: Formulary list price $0.2556/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2556 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95940 · Verify on the e-Formulary ↗ (DIN 02470438)
Source record
DIN 02470438: Sandoz Perindopril Erbumine/Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800264; group id 344; item number 0782; lccId None; manufacturer id SDZ
Source form: Tab; strength: 4mg & 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2556; ministry $0.2556
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02470438
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95940
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02297574 · $0.2556
Coversyl Plus · DIN 02246569 · $0.2556
Jamp Perindopril / Indapamide · DIN 02554127 · $0.2556
PMS-Perindopril-Indapamide · DIN 02538008 · $0.2556
Perindopril Erbumine/Indapamide · DIN 02479834 · $0.2556
Perindopril/Indapamide · DIN 02519720 · $0.2556
Teva-Perindopril/Indapamide · DIN 02464020 · $0.2556
Shortage status: resolved shortage (ended 2019-09-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02470438
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Perindopril/Indapamide · DIN 02464020 · 4mg & 1.25mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Perindopril/Indapamide · DIN 02464020
Manufacturer: Teva Canada Limited; listing date 2018-04-30
Health Canada: Marketed since 2018-03-07 · brand TEVA-PERINDOPRIL/INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients INDAPAMIDE 1.25 MG, PERINDOPRIL ERBUMINE 4 MG · company Teva canada limited · schedule Prescription
Teva-Perindopril/Indapamide: Formulary list price $0.2556/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2556 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95216 · Verify on the e-Formulary ↗ (DIN 02464020)
Source record
DIN 02464020: Teva-Perindopril/Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800264; group id 344; item number 0782; lccId None; manufacturer id TEV
Source form: Tab; strength: 4mg & 1.25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2556; ministry $0.2556
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02464020
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95216
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02297574 · $0.2556
Coversyl Plus · DIN 02246569 · $0.2556
Jamp Perindopril / Indapamide · DIN 02554127 · $0.2556
PMS-Perindopril-Indapamide · DIN 02538008 · $0.2556
Perindopril Erbumine/Indapamide · DIN 02479834 · $0.2556
Perindopril/Indapamide · DIN 02519720 · $0.2556
Sandoz Perindopril Erbumine/Indapamide · DIN 02470438 · $0.2556
Shortage status: resolved shortage (ended 2026-04-08); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02464020
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Perindopril-Indapamide · DIN 02453061 · 8mg & 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Perindopril-Indapamide · DIN 02453061
Manufacturer: Apotex Inc.; listing date 2021-03-29
Health Canada: Marketed since 2021-02-02 · brand APO-PERINDOPRIL-INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 8 MG, INDAPAMIDE 2.5 MG · company Apotex inc · schedule Prescription
Apo-Perindopril-Indapamide: Formulary list price $0.2859/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2859 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93947 · Verify on the e-Formulary ↗ (DIN 02453061)
Source record
DIN 02453061: Apo-Perindopril-Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800283; group id 344; item number 0783; lccId None; manufacturer id APX
Source form: Tab; strength: 8mg & 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2859; ministry $0.2859
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02453061
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93947
Interchangeable products
Coversyl Plus HD · DIN 02321653 · $0.2859
Jamp Perindopril / Indapamide · DIN 02554135 · $0.2859
PMS-Perindopril-Indapamide · DIN 02537982 · $0.2859
Perindopril Erbumine/Indapamide HD · DIN 02479842 · $0.2859
Perindopril/Indapamide · DIN 02519739 · $0.2859
Sandoz Perindopril Erbumine/IndapamideHD · DIN 02470446 · $0.2859
Teva-Perindopril/Indapamide · DIN 02464039 · $0.2859
Shortage status: active shortage (reported 2025-10-08, last updated 2025-10-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453061
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Coversyl Plus HD · DIN 02321653 · 8mg & 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Coversyl Plus HD (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up.
(innovicares.ca ↗)1 brand, same coverage
Coversyl Plus HD · DIN 02321653
Manufacturer: Servier Canada Inc.; listing date 2010-04-23
Health Canada: Marketed since 2009-05-07 · brand COVERSYL PLUS HD · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 8 MG, INDAPAMIDE 2.5 MG · company Servier canada inc · schedule Prescription
Ministry pays: $0.2859 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80705 · Verify on the e-Formulary ↗ (DIN 02321653)
Source record
DIN 02321653: Coversyl Plus HD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800283; group id 344; item number 0783; lccId None; manufacturer id SEV
Source form: Tab; strength: 8mg & 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.3927; ministry $0.2859
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02321653
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=80705
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02453061 · $0.2859
Jamp Perindopril / Indapamide · DIN 02554135 · $0.2859
PMS-Perindopril-Indapamide · DIN 02537982 · $0.2859
Perindopril Erbumine/Indapamide HD · DIN 02479842 · $0.2859
Perindopril/Indapamide · DIN 02519739 · $0.2859
Sandoz Perindopril Erbumine/IndapamideHD · DIN 02470446 · $0.2859
Teva-Perindopril/Indapamide · DIN 02464039 · $0.2859
Shortage status: resolved shortage (ended 2026-06-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02321653
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Perindopril / Indapamide · DIN 02554135 · 8mg & 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Perindopril / Indapamide · DIN 02554135
Manufacturer: Jamp Pharma Corporation; listing date 2026-01-30
Health Canada: Marketed since 2025-12-16 · brand JAMP PERINDOPRIL/INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients INDAPAMIDE 2.5 MG, PERINDOPRIL ERBUMINE 8 MG · company Jamp pharma corporation · schedule Prescription
Jamp Perindopril / Indapamide: Formulary list price $0.2859/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2859 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104301 · Verify on the e-Formulary ↗ (DIN 02554135)
Source record
DIN 02554135: Jamp Perindopril / Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800283; group id 344; item number 0783; lccId None; manufacturer id JPC
Source form: Tab; strength: 8mg & 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2859; ministry $0.2859
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02554135
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=104301
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02453061 · $0.2859
Coversyl Plus HD · DIN 02321653 · $0.2859
PMS-Perindopril-Indapamide · DIN 02537982 · $0.2859
Perindopril Erbumine/Indapamide HD · DIN 02479842 · $0.2859
Perindopril/Indapamide · DIN 02519739 · $0.2859
Sandoz Perindopril Erbumine/IndapamideHD · DIN 02470446 · $0.2859
Teva-Perindopril/Indapamide · DIN 02464039 · $0.2859
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02554135
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Perindopril-Indapamide · DIN 02537982 · 8mg & 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Perindopril-Indapamide · DIN 02537982
Manufacturer: Pharmascience Inc.; listing date 2023-10-31
Health Canada: Marketed since 2023-08-29 · brand PMS-PERINDOPRIL-INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients INDAPAMIDE 2.5 MG, PERINDOPRIL ERBUMINE 8 MG · company Pharmascience inc · schedule Prescription
PMS-Perindopril-Indapamide: Formulary list price $0.2859/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2859 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102675 · Verify on the e-Formulary ↗ (DIN 02537982)
Source record
DIN 02537982: PMS-Perindopril-Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800283; group id 344; item number 0783; lccId None; manufacturer id PMS
Source form: Tab; strength: 8mg & 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2859; ministry $0.2859
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02537982
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102675
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02453061 · $0.2859
Coversyl Plus HD · DIN 02321653 · $0.2859
Jamp Perindopril / Indapamide · DIN 02554135 · $0.2859
Perindopril Erbumine/Indapamide HD · DIN 02479842 · $0.2859
Perindopril/Indapamide · DIN 02519739 · $0.2859
Sandoz Perindopril Erbumine/IndapamideHD · DIN 02470446 · $0.2859
Teva-Perindopril/Indapamide · DIN 02464039 · $0.2859
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02537982
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Perindopril Erbumine/Indapamide HD · DIN 02479842 · 8mg & 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Perindopril Erbumine/Indapamide HD · DIN 02479842
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2022-03-31
Health Canada: Marketed since 2022-01-20 · brand PERINDOPRIL ERBUMINE/ INDAPAMIDE HD · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients PERINDOPRIL ERBUMINE 8 MG, INDAPAMIDE 2.5 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Perindopril Erbumine/Indapamide HD: Formulary list price $0.2859/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2859 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97042 · Verify on the e-Formulary ↗ (DIN 02479842)
Source record
DIN 02479842: Perindopril Erbumine/Indapamide HD
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800283; group id 344; item number 0783; lccId None; manufacturer id SIV
Source form: Tab; strength: 8mg & 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2859; ministry $0.2859
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02479842
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97042
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02453061 · $0.2859
Coversyl Plus HD · DIN 02321653 · $0.2859
Jamp Perindopril / Indapamide · DIN 02554135 · $0.2859
PMS-Perindopril-Indapamide · DIN 02537982 · $0.2859
Perindopril/Indapamide · DIN 02519739 · $0.2859
Sandoz Perindopril Erbumine/IndapamideHD · DIN 02470446 · $0.2859
Teva-Perindopril/Indapamide · DIN 02464039 · $0.2859
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02479842
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Perindopril/Indapamide · DIN 02519739 · 8mg & 2.5mg · tablet
General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Perindopril/Indapamide · DIN 02519739
Manufacturer: Sanis Health Inc.; listing date 2022-02-28
Health Canada: Marketed since 2021-12-15 · brand PERINDOPRIL/INDAPAMIDE · ATC C09BA04 PERINDOPRIL AND DIURETICS, C09BA04 PERINDOPRIL AND DIURETICS · form Tablet · route Oral · ingredients INDAPAMIDE 2.5 MG, PERINDOPRIL ERBUMINE 8 MG · company Sanis health inc · schedule Prescription
Perindopril/Indapamide: Formulary list price $0.2859/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2859 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100897 · Verify on the e-Formulary ↗ (DIN 02519739)
Source record
DIN 02519739: Perindopril/Indapamide
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800283; group id 344; item number 0783; lccId None; manufacturer id SAI
Source form: Tab; strength: 8mg & 2.5mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.2859; ministry $0.2859
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02519739
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100897
Interchangeable products
Apo-Perindopril-Indapamide · DIN 02453061 · $0.2859
Coversyl Plus HD · DIN 02321653 · $0.2859
Jamp Perindopril / Indapamide · DIN 02554135 · $0.2859
PMS-Perindopril-Indapamide · DIN 02537982 · $0.2859
Perindopril Erbumine/Indapamide HD · DIN 02479842 · $0.2859
Sandoz Perindopril Erbumine/IndapamideHD · DIN 02470446 · $0.2859
Teva-Perindopril/Indapamide · DIN 02464039 · $0.2859
Shortage status: anticipated shortage (last updated 2026-08-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519739
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered
Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE
Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL
24:08 Hypotensive Drugs (For Diuretics See 40:28)
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab
· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab
· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab
· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab
· 14 products ·
Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab
· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab
· 2 products · General benefit · strengths: 5mg/12.5mg · Tab
· 17 products · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8) · strengths: 0.025mg, 0.1mg, 0.2mg · Tab
· 12 products · Listed, not a benefit (3), General benefit (9) · strengths: 1mg, 2mg, 4mg · Tab
· 52 products · Listed, not a benefit (1), General benefit (51) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab
· 12 products · General benefit (10), Listed, not a benefit (2) · strengths: 2.5mg, 5mg, 10mg · ER Tab, SR Tab
· 12 products · Listed, not a benefit (2), General benefit (10) · strengths: 10mg, 20mg · Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08
and 35 more
Other drugs in the same formulary class (40:28 Diuretics) and how they are covered
Matched class: 40:28 Diuretics
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: AMILORIDE HCL, METOLAZONE, SPIRONOLACTONE
Some products covered without a code (check the product listing): AMILORIDE HCL & HYDROCHLOROTHIAZIDE, CHLORTHALIDONE, FUROSEMIDE, HYDROCHLOROTHIAZIDE, HYDROCHLOROTHIAZIDE & SPIRONOLACTONE, HYDROCHLOROTHIAZIDE & TRIAMTERENE
40:28 Diuretics
· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 50mg · Tab
· 1 products · General benefit · strengths: 2.5mg · Tab
· 1 products · General benefit · strengths: 5mg · Tab
· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 5mg & 50mg · Tab
· 14 products ·
Limited Use, codes 481, 657 (2), General benefit (9), Listed, not a benefit (2),
Limited Use, codes 33 (1) · strengths: 10mg/mL, 20mg, 40mg, 500mg · Inj Sol (Preservative Free), O/L, Tab
· 12 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (2), General benefit (7) · strengths: 12.5mg, 25mg, 50mg · Tab
· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 25mg & 25mg, 50mg & 50mg · Tab
· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg & 50mg · Tab
· 8 products · General benefit · strengths: 25mg, 100mg · Tab
· 10 products · Listed, not a benefit (2),
Limited Use, codes 01 (8) · strengths: 2.5mg, 5mg · Tab
· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 15mg & 15mg, 30mg & 15mg, 45mg & 15mg, 60mg & 30mg, 90mg & 30mg · 14-Tabs Pk
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 40:28
Other drugs whose Health Canada label lists a similar indication: hypertension
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE
ACEBUTOLOL HCL · Listed, not a benefit (3), General benefit (6)
INDICATIONS AND CLINICAL USE
APO-ACEBUTOLOL is indicated for the following:
Treatment of mild to moderate hypertension.
Long-term management of patients with angina pectoris due to ischemic heart disease.
PM: https://pdf.hres.ca/dpd_pm/00047998.PDF; date October 24, 2018; DIN 02147602; fetched 2026-09-10
Product monograph
AMLODIPINE · Limited Use, codes 645, 706 (1), Off-Formulary Interchangeable, not an ODB benefit (11), General benefit (44)
1 INDICATIONS
NORVASC (amlodipine besylate tablets) is indicated for:
• Hypertension
NORVASC is indicated in the treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00071908.PDF; date AUG 02, 2023; DIN 00878928; fetched 2026-09-10
Product monograph
AZILSARTAN MEDOXOMIL · Off-Formulary Interchangeable, not an ODB benefit
1 Part 1: Healthcare Professional Information Indications
• EDARBI (azilsartan medoxomil) is an angiotensin II receptor blocker (ARB) indicated for the
treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00082489.PDF; date 2025-10-24; DIN 02381389; fetched 2026-09-10
Product monograph
BENAZEPRIL · Listed, not a benefit (3), General benefit (3)
Indications
BENAZEPRIL (benazepril hydrochloride tablets) is indicated for:
Treatment of mild to moderate essential hypertension.
PM: https://pdf.hres.ca/dpd_pm/00080887.PDF; date 2025-06-24; DIN 02273918; fetched 2026-09-10
Product monograph
CANDESARTAN CILEXETIL · General benefit
• Heart Failure
o The treatment of NYHA Class II and III heart failure with ejection fraction ≤ 40% in
addition to standard therapy, with or without an ACE inhibitor.
1.1 Pediatrics
Pediatrics (6 to 17 years of age):
• Hypertension
ATACAND is indicated for the treatment of essential hypertension in children and
adolescents 6 to 17 years of age (see 7.1.3 Pediatrics, 14 CLINICAL TRIALS).
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
• Hypertension
PM: https://pdf.hres.ca/dpd_pm/00085412.PDF; date JUL 17, 2026; DIN 02239090; fetched 2026-09-10
Product monograph
CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
ATACAND PLUS (candesartan cilexetil/hydrochlorothiazide) is indicated for:
• the treatment of essential hypertension in patients for whom combination therapy is
appropriate.
PM: https://pdf.hres.ca/dpd_pm/00076288.PDF; date JUN 18, 2001; DIN 02244021; fetched 2026-09-10
Product monograph
CHLORTHALIDONE · Listed, not a benefit (1), General benefit (2)
1 INDICATIONS
APO-CHLORTHALIDONE (chlorthalidone) is indicated for:
• Treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00069909.PDF; date MAR 14, 2023; DIN 00360279; fetched 2026-09-10
Product monograph
CILAZAPRIL & HYDROCHLOROTHIAZIDE · General benefit
1 INDICATIONS
INHIBACE PLUS (cilazapril and hydrochlorothiazide) is indicated for:
treatment of mild to moderate essential hypertension in patients for whom combination therapy
with both cilazapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00066994.PDF; date September 07, 1995; DIN 02181479; fetched 2026-09-10
Product monograph
CLONIDINE HCL · Off-Formulary Interchangeable, not an ODB benefit (7), Listed, not a benefit (2), General benefit (8)
INDICATIONS AND CLINICAL USE
TEVA-CLONIDINE (clonidine hydrochloride) is indicated for the treatment of hypertension.
PM: https://pdf.hres.ca/dpd_pm/00024986.PDF; date April 25, 2014; DIN 02046121; fetched 2026-09-10
Product monograph
ENALAPRIL MALEATE & HYDROCHLOROTHIAZIDE · Off-Formulary Interchangeable, not an ODB benefit
1 INDICATIONS
VASERETIC® (enalapril and hydrochlorothiazide) is indicated for:
Treatment of essential hypertension in patients for whom this combination therapy with
enalapril and hydrochlorothiazide is appropriate.
PM: https://pdf.hres.ca/dpd_pm/00068096.PDF; date November 4, 2022; DIN 00657298; fetched 2026-09-10
Product monograph
and 20 more
Coverage source: ON formulary extract 2026-08-26